[go: up one dir, main page]

RU97120700A - NEW PHARMACOLOGICAL APPLICATION OF ANTAGONISTS A-II RECEPTOR - Google Patents

NEW PHARMACOLOGICAL APPLICATION OF ANTAGONISTS A-II RECEPTOR

Info

Publication number
RU97120700A
RU97120700A RU97120700/14A RU97120700A RU97120700A RU 97120700 A RU97120700 A RU 97120700A RU 97120700/14 A RU97120700/14 A RU 97120700/14A RU 97120700 A RU97120700 A RU 97120700A RU 97120700 A RU97120700 A RU 97120700A
Authority
RU
Russia
Prior art keywords
compound
formula
pharmaceutical preparation
fragment
active ingredient
Prior art date
Application number
RU97120700/14A
Other languages
Russian (ru)
Other versions
RU2194505C2 (en
Inventor
Фендрикс Ларс
Петтерссон Андерс
Онеман Андерс
Original Assignee
Астра Актиеболаг (пабл)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9501881A external-priority patent/SE9501881D0/en
Application filed by Астра Актиеболаг (пабл) filed Critical Астра Актиеболаг (пабл)
Publication of RU97120700A publication Critical patent/RU97120700A/en
Application granted granted Critical
Publication of RU2194505C2 publication Critical patent/RU2194505C2/en

Links

Claims (10)

1. Применение соединения общей формулы:
Figure 00000001

где А представляет собой:
Figure 00000002

Figure 00000003

Figure 00000004

Figure 00000005

Figure 00000006

Figure 00000007

Figure 00000008

Figure 00000009

Figure 00000010

Figure 00000011

Figure 00000012

Figure 00000013

Figure 00000014

или его физиологически приемлемой соли и/или стереохимического изомера для получения лекарства с воздействием на множественное расстройство системных органов.1. The use of compounds of General formula:
Figure 00000001

where a represents:
Figure 00000002

Figure 00000003

Figure 00000004

Figure 00000005

Figure 00000006

Figure 00000007

Figure 00000008

Figure 00000009

Figure 00000010

Figure 00000011

Figure 00000012

Figure 00000013

Figure 00000014

or its physiologically acceptable salt and / or stereochemical isomer to obtain a drug with an effect on multiple disorder of systemic organs. 2. Применение по п. 1 соединения формулы 1, отличающееся тем, что А представляет собой фрагмент 1:1. 2. The use according to claim 1 of the compound of formula 1, characterized in that A is a 1: 1 fragment. 3. Применение по п. 1 соединения формулы 1, отличающееся тем, что А представляет собой фрагмент 1:. 5. 3. The use according to claim 1 of the compound of formula 1, characterized in that A is a fragment of 1 :. five. 4. Фармацевтический препарат для профилактики и лечения множественного расстройства системных органов, отличающийся тем, что активным ингредиентом является соединение, описанное в п.1. 4. Pharmaceutical preparation for the prevention and treatment of multiple disorders of systemic organs, characterized in that the active ingredient is the compound described in claim 1. 5. Фармацевтический препарат по п.4 в форме единиц дозировки. 5. The pharmaceutical preparation according to claim 4 in the form of dosage units. 6. Фармацевтический препарат по пп.4 и 5, отличающийся тем, что содержит активные ингредиенты в сочетании с фармацевтически приемлемым носителем. 6. Pharmaceutical preparation according to claims 4 and 5, characterized in that it contains the active ingredients in combination with a pharmaceutically acceptable carrier. 7. Фармацевтический препарат по пп.4-6, отличающийся тем, что содержит в качестве активного ингредиента соединение формулы 1, где А представляет собой фрагмент 1:1. 7. The pharmaceutical preparation according to claims 4-6, characterized in that it contains as an active ingredient a compound of formula 1, where A is a 1: 1 fragment. 8. Фармацевтический препарат по пп.4-6, отличающийся тем, что содержит в качестве активного ингредиента соединение формулы 1, где А представляет собой фрагмент 1:5. 8. The pharmaceutical preparation according to claims 4-6, characterized in that it contains as an active ingredient a compound of formula 1, where A is a fragment of 1: 5. 9. Способ профилактики и лечения множественного расстройства системных органов у млекопитающих, включая человека, отличающийся тем, что эффективное количество соединения по п. 1 вводится реципиенту, нуждающемуся в таких профилактике и лечении. 9. A method of preventing and treating multiple disorders of systemic organs in mammals, including humans, characterized in that the effective amount of the compound according to claim 1 is administered to the recipient in need of such prevention and treatment. 10. Способ по п.9, отличающийся тем, что вводится соединение формулы 1, где А представляет собой фрагменты 1:1 или 1:5. 10. The method according to claim 9, characterized in that the compound of formula 1 is administered, where A is fragments of 1: 1 or 1: 5.
RU97120700/14A 1995-05-19 1996-05-08 Novel pharmacological use of antagonists of a-ii receptor RU2194505C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9501881-8 1995-05-19
SE9501881A SE9501881D0 (en) 1995-05-19 1995-05-19 New pharmacological use of AII receptor antagonists

Publications (2)

Publication Number Publication Date
RU97120700A true RU97120700A (en) 1999-09-27
RU2194505C2 RU2194505C2 (en) 2002-12-20

Family

ID=20398385

Family Applications (1)

Application Number Title Priority Date Filing Date
RU97120700/14A RU2194505C2 (en) 1995-05-19 1996-05-08 Novel pharmacological use of antagonists of a-ii receptor

Country Status (23)

Country Link
US (1) US5900428A (en)
EP (1) EP0830131A1 (en)
JP (1) JPH11505243A (en)
KR (1) KR19990014905A (en)
CN (1) CN1093761C (en)
AU (1) AU706301B2 (en)
BR (1) BR9608407A (en)
CA (1) CA2219395A1 (en)
CZ (1) CZ290155B6 (en)
EE (1) EE03666B1 (en)
HU (1) HUP9900227A3 (en)
IL (1) IL118299A (en)
IS (1) IS4597A (en)
MX (1) MX9708557A (en)
MY (1) MY114428A (en)
NO (1) NO975221D0 (en)
NZ (1) NZ308260A (en)
RU (1) RU2194505C2 (en)
SE (1) SE9501881D0 (en)
SK (1) SK151397A3 (en)
TW (1) TW473389B (en)
WO (1) WO1996036336A1 (en)
ZA (1) ZA963569B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW580397B (en) * 1997-05-27 2004-03-21 Takeda Chemical Industries Ltd Solid preparation
US6514249B1 (en) 1997-07-08 2003-02-04 Atrionix, Inc. Positioning system and method for orienting an ablation element within a pulmonary vein ostium
SE9800550D0 (en) * 1998-02-24 1998-02-24 A & Science Invest Ab A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
EP1121103B1 (en) 1998-05-18 2006-12-20 Takeda Pharmaceutical Company Limited Orally disintegrable tablets comprising a benzimidazole
US20060182802A1 (en) * 1998-07-28 2006-08-17 Toshihiro Shimizu Rapidly disintegrable solid preparation
CA2400124C (en) 2000-02-18 2010-12-14 Kazuaki Ikeya Tnf-.alpha. inhibitors
CA2568640C (en) 2004-06-04 2011-08-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
KR20130074808A (en) 2011-12-16 2013-07-05 한올바이오파마주식회사 The pharmaceutical composition comprising losartan for treating or preventing statin-induced muscle toxicity
CN104261284B (en) * 2014-09-18 2016-02-03 中邮建技术有限公司 A kind of antenna hanging apparatus of wireless base station
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
KR102748938B1 (en) 2022-01-13 2025-01-03 주식회사 팔복인더스트리 Electric double layer capacitor assembly apparatus

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5138069A (en) * 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
NZ237476A (en) * 1990-03-20 1994-01-26 Sanofi Sa N-substituted heterocyclic compounds and pharmaceutical compositions.
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5098920A (en) * 1990-05-04 1992-03-24 G. D. Searle & Co. 1h-substituted-1,2,4-triazole compounds and methods of use thereof for treatment of cardiovascular disorders
US5087634A (en) * 1990-10-31 1992-02-11 G. D. Searle & Co. N-substituted imidazol-2-one compounds for treatment of circulatory disorders
US5538991A (en) * 1994-09-14 1996-07-23 Merck & Co., Inc. Endothelin antagonists bearing 5-membered heterocyclic amides

Similar Documents

Publication Publication Date Title
ATE522211T1 (en) STABILIZED FIBRATE MICROPARTICLES
EA200000468A1 (en) THERAPEUTIC COMPOSITION FOR THE ADMINISTRATION OF TOLTERODINE WITH CONTROLLED DELIVERY
RU2220723C2 (en) Agent and method for treatment or prophylaxis of arteriosclerosis
RU98111594A (en) PHARMACEUTICAL COMPOSITIONS INCLUDING FLURBIPROFEN
ES2162615T3 (en) METHOD TO TREAT OR PREVENT TYPE 1 DIABETES THROUGH ORAL INSULIN ADMINISTRATION.
RU2000100361A (en) SODIUM SALT OMEGRAZOLE
RU94046316A (en) Use of high effective phosphonates for preparing medicinal agents for osteoporosis treatment
CY1112260T1 (en) CONTROLLED HYDROCONUT PACKAGES
RU2003119545A (en) PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION OF PHAMACOLOGICAL ACTIVE SUBSTANCES
RU93058351A (en) SUBSTITUTED 3-AMINOCHINUCLIDINES, PHARMACEUTICAL COMPOSITIONS BASED ON IT, METHODS OF TREATMENT, METHOD FOR PRODUCING, INTERMEDIATE COMPOUNDS
RU94027680A (en) Parathyroid hormone and raloxifen for bone mass increase, pharmaceutical composition and method of osseous mass increase
EE04800B1 (en) Oral dosage form for acid unstable active ingredient, unit dosage form, method of preparation and use, and method for oral dosage form
ATE292982T1 (en) ANALGESIC SYNERGY THROUGH SIMULTANEOUS ADMINISTRATION OF SUBANALGESIC DOSES OF A MU-OPIOID ANAGONIST AND A KAPPA-2-OPIOID ANAGONIST
SE9301057D0 (en) CONTROLLED RELEASE PREPRATION
CA2326517A1 (en) New galenic preparations of meloxicam for oral administration
RU2005124363A (en) SOLID ORAL DOSAGE FORMS OF VALSARTAN
RU2209064C2 (en) New application in medicinal purposes
RU97120700A (en) NEW PHARMACOLOGICAL APPLICATION OF ANTAGONISTS A-II RECEPTOR
RU2002115406A (en) Compound possessing the properties of the release of growth hormone
RU98101105A (en) NEW APPLICATION FOR MEDICAL PURPOSES
RU2003136733A (en) Oral administration of parathyroid hormone and calcitonin
RU2001111808A (en) PHARMACEUTICAL COMPOSITION CONTAINING A COMBINATION OF ROTARY AND LEFT ROTARY ISOMERS OF SOTALOL
MY124465A (en) Reduction of infarct volume using citicoline
RU2003100517A (en) NEW INTERFERON FOR THE TREATMENT OF MULTIPLE SCLEROSIS
BR9509433A (en) Use of (r- (z)) - a- (metaoxyimino) -a- (1-azabicyclo- (2,2,2) oct-3-yl) acetonitrile or a pharmaceutically acceptable salt from the same process to improve the processing of an amyloid precursor protein along a non-amyloidogen pathway process for treatment or prophylaxis of alzheimer's disease pharmaceutical composition and use process or composition